Carmell Therapeutics is planning to launch a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology uses pooled plasma to create products which accelerate the healing of bone and soft tissues. As PBM breaks down within the body, it releases growth and healing factors as the body requires for healing.
To expedite commercialization, Carmell will relocate headquarters, its R&D lab and manufacturing to a new facility later this month.
Studies have indicated that use of the company’s REPAIR™ plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.
Carmell Therapeutics is planning to launch a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology uses pooled plasma to create products which accelerate the healing...
Carmell Therapeutics is planning to launch a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care.
PBM technology uses pooled plasma to create products which accelerate the healing of bone and soft tissues. As PBM breaks down within the body, it releases growth and healing factors as the body requires for healing.
To expedite commercialization, Carmell will relocate headquarters, its R&D lab and manufacturing to a new facility later this month.
Studies have indicated that use of the company’s REPAIR™ plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.
Copy to clipboard 
